Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI

被引:59
作者
Hoetker, Andreas M. [1 ,2 ]
Mazaheri, Yousef [3 ]
Aras, Oemer [1 ]
Zheng, Junting [4 ]
Moskowitz, Chaya S. [4 ]
Gondo, Tatsuo [5 ]
Matsumoto, Kazuhiro [6 ]
Hricak, Hedvig [1 ]
Akin, Oguz [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA
[2] Univ Med Mainz, Dept Diagnost & Intervent Radiol, Mainz, Germany
[3] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
关键词
DWI; MRI; prostate cancer; APPARENT DIFFUSION-COEFFICIENT; ACTIVE SURVEILLANCE; GLEASON SCORE; TUMOR VOLUME; GRADE; PARAMETERS; ADC;
D O I
10.2214/AJR.15.14912
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The objective of this study was to investigate whether the apparent diffusion coefficient (ADC) value from DWI and the forward volume transfer constant (K-trans) value from dynamic contrast-enhanced MRI independently predict prostate cancer aggressiveness, and to determine whether the combination of both parameters performs better than either parameter alone in assessing tumor aggressiveness before treatment. MATERIALS AND METHODS. This retrospective study included 158 men with histopathologically confirmed prostate cancer who underwent 3-T MRI before undergoing prostatectomy in 2011. Whole-mount step-section pathologic maps identified 195 prostate cancer foci that were 0.5 mL or larger; these foci were then volumetrically assessed to calculate the per-tumor ADC and K-trans values. Associations between MRI and histopathologic parameters were assessed using Spearman correlation coefficients, univariate and multivariable logistic regression, and AUCs. RESULTS. The median ADC and K-trans values showed moderate correlation only for tumors for which the Gleason score (GS) was 4 + 4 or higher (rho = 0.547; p = 0.042). The tumor ADC value was statistically significantly associated with all dichotomized GSs (p < 0.005), including a GS of 3 + 3 versus a GS of 3 + 4 or higher (AUC, 0.693; p = 0.001). The tumor K-trans value differed statistically significantly only between tumors with a GS of 3 + 3 and those with a primary Gleason grade of 4 (p <= 0.015), and it made a statistically significant contribution only in differentiating tumors with a GS of 4 + 3 or higher (AUC, 0.711; p < 0.001) and those with a GS of 4 + 4 or higher (AUC, 0.788; p < 0.001) from lower-grade tumors. Combining ADC and K-trans values improved diagnostic performance in characterizing tumors with a GS of 4 + 3 or higher and those with a GS of 4 + 4 or higher (AUC, 0.739 and 0.856, respectively; p < 0.01). CONCLUSION. Although the ADC value helped to differentiate between all GSs, the K-trans value was only a benefit in characterizing more aggressive tumors. Combining these parameters improves their performance in identifying patients with aggressive tumors who may require radical treatment.
引用
收藏
页码:756 / 763
页数:8
相关论文
共 50 条
[21]   Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study [J].
Sabouri, Shirin ;
Chang, Silvia D. ;
Goldenberg, S. Larry ;
Savdie, Richard ;
Jones, Edward C. ;
Black, Peter C. ;
Fazli, Ladan ;
Kozlowski, Piotr .
NMR IN BIOMEDICINE, 2019, 32 (02)
[22]   Assessment of ameloblastomas using MRI and dynamic contrast-enhanced MRI [J].
Asaumi, J ;
Hisatomi, M ;
Yanagi, Y ;
Matsuzaki, H ;
Choi, YS ;
Kawai, N ;
Konouchi, H ;
Kishi, K .
EUROPEAN JOURNAL OF RADIOLOGY, 2005, 56 (01) :25-30
[23]   Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Characterization of the Index Lesion With Multiparametric MRI in Prostate Cancer Patients [J].
Yuan, Qing ;
Costa, Daniel N. ;
Senegas, Julien ;
Xi, Yin ;
Wiethoff, Andrea J. ;
Rofsky, Neil M. ;
Roehrborn, Claus ;
Lenkinski, Robert E. ;
Pedrosa, Ivan .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2017, 45 (03) :908-916
[24]   Reference region extraction by clustering for the pharmacokinetic analysis of dynamic contrast-enhanced MRI in prostate cancer [J].
Ikoma, Yoko ;
Kishimoto, Riwa ;
Tachibana, Yasuhiko ;
Omatsu, Tokuhiko ;
Kasuya, Goro ;
Makishima, Hirokazu ;
Higashi, Tatsuya ;
Obata, Takayuki ;
Tsuji, Hiroshi .
MAGNETIC RESONANCE IMAGING, 2020, 66 :185-192
[25]   Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer [J].
Chung, Melody P. ;
Margolis, Dan ;
Mesko, Shane ;
Wang, Jason ;
Kupelian, Patrick ;
Kamrava, Mitchell .
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2014, 58 (05) :588-594
[26]   Impact of contrast agent injection duration on dynamic contrast-enhanced MRI quantification in prostate cancer [J].
Klawer, Edzo M. E. ;
van Houdt, Petra J. ;
Pos, Floris J. ;
Heijmink, Stijn W. T. P. J. ;
van Osch, Matthias J. P. ;
van der Heide, Uulke A. .
NMR IN BIOMEDICINE, 2018, 31 (09)
[27]   Dynamic contrast enhanced MRI in prostate cancer [J].
Alonzi, Roberto ;
Padhani, Anwar R. ;
Allen, Clare .
EUROPEAN JOURNAL OF RADIOLOGY, 2007, 63 (03) :335-350
[28]   Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer [J].
Wildeboer, Rogier R. ;
Postema, Arnoud W. ;
Demi, Libertario ;
Kuenen, Maarten P. J. ;
Wijkstra, Hessel ;
Mischi, Massimo .
EUROPEAN RADIOLOGY, 2017, 27 (08) :3226-3234
[29]   Multiparametric Dynamic Contrast-Enhanced Ultrasound Classification of Prostate Cancer [J].
Wildeboer, R. R. ;
Postema, A. W. ;
Demi, L. ;
Kuenen, M. P. J. ;
Wijkstra, H. ;
Mischi, M. .
2016 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS), 2016,
[30]   Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer [J].
Wang, Xiangyu ;
Tu, Ning ;
Qin, Tao ;
Xing, Fen ;
Wang, Panying ;
Wu, Guangyao .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (04) :797-804